Blog
Valuable TargetsAdvanced Tech.
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
BW-05 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
8 min read
BW-05 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
1 September 2026
BW-05: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Read →
ILB(Tikomed) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
8 min read
ILB(Tikomed) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
1 September 2026
ILB(Tikomed): Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Read →
IPP-204106 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
8 min read
IPP-204106 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
1 September 2026
IPP-204106: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Read →
COYA-301 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
8 min read
COYA-301 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
1 September 2026
COYA-301: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Read →
[99mTc]Tc(CO)3-(HE)3-Ec1 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
8 min read
[99mTc]Tc(CO)3-(HE)3-Ec1 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
1 September 2026
[99mTc]Tc(CO)3-(HE)3-Ec1: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Read →
PLN-101095 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
8 min read
PLN-101095 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
1 September 2026
PLN-101095: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Read →
NBI-355 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
8 min read
NBI-355 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
1 September 2026
NBI-355: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Read →
Kappa-CD28-T-cells(Baylor College of Medicine) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
8 min read
Kappa-CD28-T-cells(Baylor College of Medicine) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
1 September 2026
Kappa-CD28-T-cells(Baylor College of Medicine): Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals.
Read →
OC-514 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
8 min read
OC-514 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
1 September 2026
OC-514: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Read →
SHR-1654 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
8 min read
SHR-1654 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
1 September 2026
SHR-1654: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Read →
68Ga-LNC1007 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
8 min read
68Ga-LNC1007 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
1 September 2026
68Ga-LNC1007: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Read →
Bioengineered Internal Anal Sphincter(Cellf Bio LLC) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
8 min read
Bioengineered Internal Anal Sphincter(Cellf Bio LLC) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
1 September 2026
Bioengineered Internal Anal Sphincter(Cellf Bio LLC): Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals.
Read →